Optimizing Ablative Modality for Treatment Outcome: Quid Quando Ubi

How to cite: Taneja SS. Optimizing Ablative Modality for Treatment Outcome: Quid Quando Ubi. Grand Rounds in Urology. October 2025. Accessed Oct 2026. https://grandroundsinurology.com/optimizing-ablative-modality-for-treatment-outcome-quid-quando-ubi/

Summary

Samir S. Taneja, MD, Waldbaum Gardner Professor and Chair of Urology, Professor of Radiology, Donald and Susan Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, presents a framework to guide the optimization of ablative therapy through the principles of Quid Quando Ubi. The approach emphasises the nature of the disease being treated, the timing and sequence of evaluation and therapy, and the anatomic environment in which treatment is delivered. He explains that the success of focal therapy depends on clear objectives, including the control of clinically significant disease, preservation of functional outcomes, and avoidance of metastatic progression.

He describes how ablative modalities differ in their mechanisms of action, energy deposition, and precision, and that aligning modality characteristics with tumor attributes is central to effective treatment. Tumor size, focal nature, proximity to critical structures, and imaging visibility all influence suitability for thermal or non-thermal modalities. He notes that variations in magnetic resonance imaging conspicuity and histologic composition affect lesion detectability and thus influence treatment planning.

Dr. Taneja discusses procedural sequencing, emphasizing that biopsy confirmation, imaging review, and treatment selection must follow a logical progression. He highlights that technology selection must consider lesion accessibility, treatment field geometry, and safety boundaries. He stresses that different modalities impose different constraints regarding margins, heat sink effects, precision limits, and anatomic tolerances.

Dr. Taneja states that focal therapy outcomes depend on matching each modality to lesions that can be treated completely, safely, and reproducibly. Favourable lesion characteristics include discrete size, clear imaging definition, and a safe distance from structures where risks to function would be unacceptable. He argues that optimization requires integrating disease attributes, technology capabilities, and anatomic context to achieve consistent and durable focal therapy outcomes.

Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.